Last reviewed · How we verify

NCT03747926

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated

Withdrawn Phase 1 Last updated 15 November 2021
What this trial tests

Phase 1 trial testing BI 705564 in Healthy. Withdrawn.

Timeline
5 April 2019
Primary endpoint
12 August 2019
2 September 2019

Quick facts

Lead sponsorBoehringer Ingelheim
PhasePhase 1
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Start date5 April 2019
Primary completion12 August 2019
Estimated completion2 September 2019

Drugs / interventions tested

Conditions studied

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

Adults 20 to 50, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this trial is to investigate the safety and tolerability of BI 705564 in healthy male subjects following oral administration of single rising doses. A secondary objective is the exploration of the PK including dose proportionality of BI 705564 after single dosing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of BI 705564

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Boehringer Ingelheim trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03747926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing